Granules India reports 7.8 percent rise in Q4 profit
Bengaluru: Granules India reported a 7.8 per cent rise in fourth-quarter profit, spurred by strong growth in its business of making active pharmaceutical ingredient (API) for drugs.
The company's consolidated net profit rose to 1.20 billion rupees ($14.7 million) in the quarter ended March 31, from 1.11 billion rupees a year earlier.
Granules's consolidated revenue from operations rose 16 per cent to 11.96 billion rupees, but a 17 per cent jump in its total expenses ate into the profit growth.
The company's revenue from finished dosages, its largest division, rose 16 per cent year-on-year, but that was easily outpaced by its API segment, its second-biggest, where revenue jumped 48 per cent.
Granules reported a 38 per cent jump in sales of paracetamol, which is both an API and a ready-for-consumption drug it sells only in the European Union.
However, the company's biggest market is the United States, from where it gets 31 per cent. The drugs it sells in the country includes skeletal muscle relaxant methocarbamol, whose sales surged 60 per cent in the quarter.
Last month, Glenmark Life Sciences Ltd posted a 48 per cent rise in quarterly profit, driven by growth in its mainstay API business. Granules's shares were down 1.6 per cent after the results
Read also: Granules Consumer Health launches packaging facility in US
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd